Abstract: The presently described subject matter is based on the finding that inhibition of eotaxin-2 by polyclonal or monoclonal antibodies, has a significant protective effect in animal models of inflammatory diseases such as rheumatoid arthritis, experimental autoimmune encephalomyelitis (EAE), colitis, diabetes, and atherosclerosis. Thus, provided are pharmaceutical compositions including specific anti-eotaxin 2 antibodies for use alone or in combination with other therapeutic agents in the treatment of inflammatory, autoimmune and cardiovascular diseases. Also provided are specific anti-eotaxin-2 monoclonal antibodies, and methods of treatment utilizing such antibodies.
Type:
Application
Filed:
January 28, 2010
Publication date:
November 17, 2011
Applicant:
THE MEDICAL RESEARCH, INFRASTRUCTURE, AND HEALTH S ERNICES FUND OF THE TEL AVIV MEDICAL CENTER